Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

Core Insights - Akari Therapeutics has formed a Scientific Advisory Board (SAB) and appointed Dr. Sara Hurvitz as its inaugural member, which is a significant step in advancing the company's scientific and clinical strategy [2][4] Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing novel payload antibody drug conjugates (ADCs) [1][9] - The company is expanding its ADC pipeline to include multiple targets, such as AKTX-101, which is a Trop2 ADC with a PH1 payload, and future programs like AKTX-102 with an undisclosed target [8][9] Leadership and Expertise - Dr. Sara Hurvitz is an internationally recognized expert in oncology, particularly in the clinical development of ADCs and targeted therapies for breast cancer [4][6] - She currently serves as Professor of Medicine and Division Head of Hematology/Oncology at the University of Washington School of Medicine and has a distinguished career in leading global clinical trials [5][6] Scientific Contributions - Dr. Hurvitz's expertise includes management of cancers at all stages, with a focus on neoadjuvant treatments and targeted therapies for various breast cancer types [2][4] - She has emphasized the transformative impact of ADCs in oncology, particularly in breast cancer, and is optimistic about Akari's preclinical data [2][4] Product Development - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a novel PH1 payload designed to disrupt RNA splicing, which has shown significant activity in preclinical studies [9] - The company aims to advance its lead asset and other undisclosed targets with this innovative payload, which has demonstrated potential synergy with checkpoint inhibitors [9]